Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kaitlyn R Rubnitz"'
Autor:
Olivia M Padovan-Merhar, Pichai Raman, Irina Ostrovnaya, Karthik Kalletla, Kaitlyn R Rubnitz, Eric M Sanford, Siraj M Ali, Vincent A Miller, Yael P Mossé, Meaghan P Granger, Brian Weiss, John M Maris, Shakeel Modak
Publikováno v:
PLoS Genetics, Vol 12, Iss 12, p e1006501 (2016)
Neuroblastoma is characterized by a relative paucity of recurrent somatic mutations at diagnosis. However, recent studies have shown that the mutational burden increases at relapse, likely as a result of clonal evolution of mutation-carrying cells du
Externí odkaz:
https://doaj.org/article/75355ff9bcc04b46a261aca7d6e29c7c
Autor:
Justin C. Brown, Zi Zhang, Andrea B. Troxel, Joshua Bauml, Bert W. O'Malley, Gregory S. Weinstein, Kaitlyn R. Rubnitz, Kathryn H. Schmitz, Colleen M. Grosso
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 24(5)
Incidence of head and neck cancer (HNC) due to human papillomavirus (HPV) infection has been increasing. Treatment regimens have evolved. These changes might result in alterations of assumed treatment-related weight changes for HNC patients. We aimed
Autor:
Yael P. Mosse, Olivia M. Padovan-Merhar, Brian Weiss, Shakeel Modak, Karthik Kalletla, John M. Maris, Vincent A. Miller, Kaitlyn R. Rubnitz, Meaghan Granger, Siraj M. Ali, Irina Ostrovnaya, Pichai Raman, Eric M. Sanford
Publikováno v:
PLoS Genetics
PLoS Genetics, Vol 12, Iss 12, p e1006501 (2016)
PLoS Genetics, Vol 12, Iss 12, p e1006501 (2016)
Neuroblastoma is characterized by a relative paucity of recurrent somatic mutations at diagnosis. However, recent studies have shown that the mutational burden increases at relapse, likely as a result of clonal evolution of mutation-carrying cells du
Autor:
Kaitlyn R. Rubnitz, Shakeel Modak, Vincent A. Miller, Olivia M. Padovan-Merhar, Yael P. Mosse, Brian Weiss, Siraj M. Ali, Meaghan Granger, Pichai Raman, John M. Maris
Publikováno v:
Cancer Research. 76:2431-2431
Neuroblastoma (NB) is a pediatric tumor responsible for 15% of pediatric cancer deaths. Patients with relapsed high-risk disease have less than a 5% chance of survival despite intensive cytotoxic chemotherapy regimens. Personalized therapies targeted